KRAS and non-small cell lung carcinoma: TKIs are used in patients with metastatic NSCLC (stage III or IV) and certain gene alterations, including EGFR, ALK, ROS1, NTRK1, BRAF, HER2, MET, and KRAS genes, which are independent of PD-L1 levels.